Merck Life Sciences Acquires HUB Organoids
The Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for more faster and more effective drug development. Terms of the deal were not disclosed.
“The use of organoids offers tremendous potential to improve the drug discovery process,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “HUB’s advanced technology, combined with our cell culture expertise and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of 3D cell culture to understand the impact of drug response earlier in the development process.”
HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing Merck KGaA, Darmstadt, Germany´s offering of cell culture tools to academia, biotech, and pharma customers. The team of approximately 70 employees is celebrating the acquisition together at the HUB campus in Utrecht, Netherlands.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Olympic champion Maarten van der Weijden swims one last time, now for the Máxima
Maarten van der Weijden is putting on his swimming suit one last time to raise money for cancer research. From 17 to 22 August, he will swim an incredible 270 kilometers through 22 cities, with the Princess Máxima Center as his final destination. With this special challenge, he is raising money for pioneering research into the immediate and long-term effects of childhood cancer.
New exit for construction traffic at the Utrecht Science Park
Various construction works are taking place in the north-west cluster of Utrecht Science Park. This is the area where the Minnaert Building and the Buys Ballot Building, amongst others, are located. To ensure that construction traffic flows more safely and efficiently through the area, a new exit is being constructed from Sorbonnelaan to Leuvenlaan.
Eliminating cancer with light
Killing tumors with light. Is that something for the distant future? Certainly not! UMC Utrecht and start-up Lumox are now going to test an innovative therapy in a first patient study.
Opening Utrecht Science Week with keynote by Juliette Legler on the hidden influence of environmental chemicals
On Friday, September 25, the annual science festival ‘Utrecht Science Week’ kicks off once again at Utrecht Science Park. We are pleased to announce that this year, Prof. Dr. Ir. Juliette Legler will deliver the Utrecht Science Lecture. Juliette Legler is Professor of Toxicology at the Faculty of Veterinary Medicine at Utrecht University and leads the ‘One Health Toxicology’ group at the Institute for Risk Assessment Sciences (IRAS).